Praxis and Relmada target depression as Athira and Taurx tackle Alzheimer’s.
But the pipeline contains various approaches that are worth watching, with data from Abbvie possibly the next big event.
The company’s off-the-shelf T-cell immunotherapy seems to be improving multile sclerosis disability, but an ongoing phase 2 trial will provide a better test.
Two arm’s-length acquisitions and two licensing deals have given Bayer a cell and gene therapy unit; now to bring it all together.
IGM’s snowballing share price belies some other major Ash winners, and will make Christmas unhappy for funds that had shorted the stock.
Two progressive multiple sclerosis subjects in a high-dose six-patient cohort given ATA188 have seen their disease reverse.
Atara tackles multiple sclerosis’s virus hypothesis while Aslan needs to roar with crucial biliary tract cancer data.
A Baylor College study suggests to investors what Bellicum’s upcoming first-in-human trial of BPX-603 will have to match.
A run of acquisitions of recent biotech IPOs is great news for investors who backed these companies, but the reality is that a large majority of fledgling drug stocks are…